

**ESSENTIAL HEALTH BENEFIT OVERVIEW & APPLICATION PROCESS** 

WA EHB Benchmark Plan

#### PRESENTED BY:

Julie Peper, FSA, MAAA julie.peper@wakely.com

Jenna Stefan, ASA, MAAA jenna.stefan@wakely.com

Matt Sauter, ASA, MAAA matt.sauter@wakely.com



### Agenda

Overview of Federal Regulations on EHB

Benefit Pricing: Benefits for Consideration

Wakely Process

**Project Timeline** 

**Disclosures and Limitations** 

Additional EHB Regulations and Information





# Overview of Federal Regulations on EHB



Under 45 CFR 156.111 states may select a new EHB-benchmark plan (BMP) for 2020 BY or later (finalized in 2019 NBPP) using one of 3 options

- Select an EHB-benchmark that another plan used for the 2017 BY
- Replace one or more categories of EHB with another 2017 BY BMP
- Select a new set of benefits to become the state's EHB-benchmark plan, provided certain conditions are met

To date, <u>all</u> updates to state EHB benchmarks has used method #3 May 4, 2024, application deadline for BY 2026 (as finalized in the 2023 NBPP)

- Provide reasonable public comment period
- Submit supporting documentation
- Fulfill typicality and generosity standards



Typicality and Generosity Tests

Generally, there are two actuarial requirements the proposed benchmark plan must meet – the typicality and generosity test:

#### Typicality Test

 Provides a scope of benefits in the new EHB-benchmark plan that are equal to the scope of benefits provided under a typical employer plan selected by the state

#### **Generosity Test**

- Ensures the new EHB-benchmark plan does not exceed the generosity of the most generous among a set of comparison plans
- The costs (i.e., actuarial value) of the new plan cannot exceed the cost of the most generous plan at all (0.0%)



Typicality Test

#### Step 1

Select a typical employer plan among the options at §156.111(b)(2)(i): These options include:

- •One of the state's 10 base-benchmark plan options established at 156.100 from which the state was able to select for the 2017 plan year; or
- •One of the five largest group plans provided the plans meet certain requirements like benefits in the plan are from a plan year beginning after December 31, 2013

#### Step 2

Calculate the expected value of covering all of the benefits at 100 percent actuarial value in the proposed EHB-benchmark plan and in the typical employer plan, including any necessary supplementation for plans to meet EHB standards

#### Step 3

Compare the expected value of covering all of the benefits (at 100 percent actuarial value) in the typical employer plan to that of the state's proposed EHB-benchmark plan



**Generosity Test** 

#### Step 1

Determine the most generous plan among the set of comparison plans

■The Comparison plans include the EHB-benchmark plan used by the state in 2017, and any of the state's base-benchmark plan options for the 2017 plan year, supplemented as necessary to meet EHB standards at 156.100

#### Step 2

Calculate the expected value of covering all of the benefits at 100 percent actuarial value in the proposed EHB-benchmark plan and in the most generous plan among the set of comparison plans, including any necessary supplementation to meet EHB standards (156.100)

#### Step 3

Compare the expected value of covering all of the benefits (at 100 percent actuarial value) in the most generous plan among the set of comparison plans to that of the proposed state's EHB-benchmark plan



### Other Changes

Other Federal Requirements

Beyond Federal regulations, CMS often requests states to "clean up" the benchmark documentation to ensure that all documentation around the benchmark plan aligns with EHB standards at 156.100, 156.122, and 156.125.

#### This often includes:

of potentially discriminatory language (156.100 and 156.125) Alignment of prescription drug formulary with requirements at 156.122

 This often includes adding drugs so that there is one drug in every United States Pharmacopeia (USP) category and class Removal of any issuerspecific identifications on the materials

Any other changes requested by CMS



### Changes to EHB

# Benefit Pricing



### **Benefit Pricing & Selection**

Changes to EHB

#### **Benefit Selection Process**

Evaluation of the value of each benefit being considered for inclusion in 2026 benchmark (using ACA data, publicly available data, and actuarial judgement)

Comparison of newly proposed benchmark plan against generosity test such that benefit changes do not result in the new EHB plan being richer than the most generous plan included in the generosity testing

- EHB focuses on the allowed cost of services, which is the overall cost of the benefit (combined cost of the insurer paid amount and member cost sharing)
- Ultimately, the premium impact of the changes will vary based on insurer pricing, cost sharing
  of the benefits, and changes, if any, to administrative costs due to the changes

Additionally, the proposed benchmark must pass the typicality test



### **Benefit Pricing & Selection**

**Discriminatory Considerations** 

Potential changes to address discriminatory benefit design; these changes are likely not considered changes to the EHB Benchmark plan (as defined at 156.110(d) and 156.125)

#### **Foot Care**

 Current benefit excludes foot care except for diabetics. Revised language could specify as medically necessary.

#### Lifetime maximums

 Ensure no lifetime maximums that are not allowed under federal regulations

#### Acupuncture

 Ensure no exclusions or limits on the benefit that are different for specified conditions unless medically justified Additional discriminatory language may be identified



### **Benefit Pricing & Selection**

Benefit Changes Considered Based on Stakeholder Feedback

# Pursuant to SSB 5338, the following benefits should be considered

Donor human milk

Treatment for Pediatric Acute-onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections;

Hearing instruments and associated services

Fertility services

Biomarker testing

Contralateral prophylactic mastectomies

Magnetic resonance imaging for breast cancer screening






# Wakely Process



### Wakely Process

Overview





# **Project Timeline**



### **Project Timeline**

Task	Description	Completion Date
Kickoff Call	Introduce team and discuss project and timeline	7/26/2023
National & Regional BMP Overview	Overview of national BMPs, regional comparisons, and recent EHB changes.	8/10/2023 - Draft
		8/17/2023 - Feedback
		8/24/2023 - Final
Current EHB Analysis	Review of potential discriminatory language in the current benefits	8/17/2023 - Draft
		8/24/2023 - Feedback
		8/31/2023 - Final
Wakely Receives BMP Plan Documents	Wakely receives complete set of 2017 detailed plan documents for the 10 benchmark	
	plan options for use in generosity testing (specifically need 3 small group plans, state	9/7/2023
	options, and any large group plans desired)	
Generosity and Typicality Testing	Wakely provides high-level comparison of benefits between current BMP and 10 BMP options to understand the approximate richness of the richest plan	9/11/2023 - Draft Generosity
		Test Results Submitted to OIC
		9/21/2023 - OIC Provide
		Feedback on Generosity Test
		Results
		Late Sep Public Meeting to
		Review Findings
		9/28/2023 - Final
Presentation of Deliverables 1 & 2	Document that pulls all of the analyses together for Phases 1 and 2:  1) notable differences comparison to other states, discriminatory review, and stakeholder input;  2) results of generosity testing;	End of Sep Draft
		Early Oct. Feedback
		Mid October - Final
	3) high level discussion on potential room	



### **Next Steps in Analysis**

Review benefits that are not clear in the brochures or for the benchmark

Review benefits that are not in CMS posted benchmark or do not align with plan benefits

3

Conduct generosity and typicality analysis

4

Price benefits and confirm impact to plans



### THANK YOU

# Questions?



Julie Peper, FSA, MAAA <a href="mailto:julie.peper@wakely.com">julie.peper@wakely.com</a>



Jenna Stefan, ASA, MAAA jenna.stefan@wakely.com



Matt Sauter, ASA, MAAA matt.sauter@wakely.com

Regulations and Information

## **Disclosures and Limitations**



### **Disclosures and Limitations**

- Responsible Actuaries. Julie Peper and Matt Sauter are the actuaries responsible for this document. Julie is a Fellow of the Society of Actuaries and Matt is an Associate of the Society of Actuaries. Both Julie and Matt are Members of the American Academy of Actuaries. They meet the Qualification Standards of the American Academy of Actuaries to issue this document.
- Intended Users. This information has been prepared for the sole use of the Washington State Office of the Insurance Commissioner. Distribution to parties should be made in its entirety and should be evaluated only by qualified users. The parties receiving this document should retain their own actuarial experts in interpreting results.
- Risks and Uncertainties. The assumptions and resulting estimates included in this document and produced by the modeling are inherently uncertain. Users of the results should be qualified to use it and understand the results and the inherent uncertainty. Actual results may vary, potentially materially, from our estimates. Wakely does not warrant or guarantee that Washington and/or the issuers will attain the estimated values included in the document. It is the responsibility of those receiving this output to review the assumptions carefully and notify Wakely of any potential concerns.
- Conflict of Interest. Wakely provides actuarial services to a variety of clients throughout the health industry. Our clients include commercial, Medicare, and Medicaid health plans, the federal government and state governments, medical providers, and other entities that operate in the domestic and international health insurance markets. Wakely has implemented various internal practices to reduce or eliminate conflict of interest risk in serving our various clients. Except as noted here, the responsible actuaries are financially independent and free from conflict concerning all matters related to performing the actuarial services underlying this analysis.
- Data and Reliance. The current cost estimates rely on data provided obtained in the Wakely proprietary data set, online publications, and third party subject matter experts. As such, we have relied on others for data and assumptions used in the assignment. We have reviewed the data for reasonableness, but have not performed any independent audit or otherwise verified the accuracy of the data/information. If the underlying information is incomplete or inaccurate, our estimates may be impacted, potentially significantly.
- Subsequent Events. These analyses are based on the implicit assumption that the ACA will continue to be in effect in future years with no material change. Material changes in state or federal laws regarding health benefit plans may have a material impact on the results included in this report. Material changes as a result of Federal or state regulations may also have a material impact on the results. There are no specifically known relevant events subsequent to the date of engagement that would impact the results of this document.
- Contents of Actuarial Report. This document is not an actuarial report and does not comply with Actuarial Standards of Practice on communication. Once the
  analysis is complete, a full report will be provided the lists all data and assumptions used in the comparison of benefits for purposes of supporting EHB changes to
  CMS.



### Links & Resources

#### **CMS EHB Reference Page**

https://www.cms.gov/CCIIO/Resources/Data-Resources/ehb

#### CMS' EHB Process Overview (February 2021)

https://www.regtap.info/uploads/library/PMSC\_Slides\_022421\_5CR\_022421.pdf

